Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 25;77(Suppl 2):ii1-ii2.
doi: 10.1093/jac/dkac350.

Foreword

A Pagliuca  1 , M Akova  2
Affiliations

Foreword

A Pagliuca et al. J Antimicrob Chemother. .
No abstract available

PubMed Disclaimer

References

    1. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49Suppl 1: 21–30. 10.1093/jac/49.suppl_1.21 - DOI - PubMed
    1. Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993; 3: 429–50. 10.3109/08982109309150729 - DOI
    1. Brüggemann RJ, Jensen GM, Lass-Flörl C. Liposomal amphotericin B—the past. J Antimicrob Chemother 2022; 77 Suppl 2: ii3–ii10 - PMC - PubMed
    1. Stone NR, Bicanic T, Salim Ret al. . Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016; 76: 485–500. 10.1007/s40265-016-0538-7 - DOI - PMC - PubMed
    1. Hoenigl M, Sprute R, Egger Met al. . The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021; 81: 1703–29. 10.1007/s40265-021-01611-0 - DOI - PMC - PubMed

Publication types

Grants and funding